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Abstract
Purpose Uveal melanoma (UM) is an orphan cancer of high unmet medical need. Current patterns of care and surveillance 
remain unclear as they are situated in an interdisciplinary setting.
Methods A questionnaire addressing the patterns of care and surveillance in the management of patients with uveal mela-
noma was distributed to 70 skin cancer centers in Austria, Germany and Switzerland. Frequency distributions of responses 
for each item of the questionnaire were calculated.
Results 44 of 70 (62.9%) skin cancer centers completed the questionnaire. Thirty-nine hospitals were located in Germany 
(88.6%), three in Switzerland (6.8%) and two in Austria (4.5%). The majority (68.2%) represented university hospitals. 
Most patients with metastatic disease were treated in certified skin cancer centers (70.7%, 29/41). Besides, the majority of 
patients with UM were referred to the respective skin cancer center by ophthalmologists (87.2%, 34/39). Treatment and 
organization of follow-up of patients varied across the different centers. 35.1% (14/37) of the centers stated to not perform 
any screening measures.
Conclusion Treatment patterns of patients with uveal melanoma in Germany, Austria and Switzerland remain extremely 
heterogeneous. A guideline for the treatment and surveillance is urgently needed.
Keywords Uveal melanoma · Patterns of care · Cross-sectional study · Ocular melanoma · Surveillance · Follow-up · 
Treatment patterns · Background
Background
Ocular melanoma is a rare cancer condition that can develop 
as uveal or conjunctival tumors. Uveal melanoma (UM) 
represents one of the most common ocular malignancies 
among adults and accounts for about 5% of all melanoma 
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cases. Primary tumors originate from the pigment cells of 
the choroid layer, the ciliary body or iris of the eye (Chat-
topadhyay et al. 2016). With an incidence of 4–7 cases per 
million in Europe, it is much rarer than cutaneous melanoma 
(Mallone et al. 2012). Therapeutic options of local disease 
include radiation therapies or surgical approaches like local 
resection and enucleation of the affected eye. Although these 
measures are highly effective to achieve local tumor control, 
up to 50% of patients develop distant metastases, which are 
mostly localized to liver and lungs (Bedikian 2006).
Risk for metastases strongly depends on monosomy 3 
(Shields et al. 2011). Once UM becomes metastatic, the dis-
ease course is often aggressive and the prognosis is dismal 
with an average survival time of 1 year across all therapeu-
tic regimens (Rantala et al. 2019). A combined approach 
with local treatment and combined immunotherapy has been 
employed with a median overall survival of 18 months in 
a small group of patients (Kirchberger et al. 2018). Thus, 
therapy options remain limited and have often been adopted 
from cutaneous melanoma, although these entities differ 
clinically and genetically (Heppt et al. 2017b). Few inter-
vention studies have been published for UM and sound 
randomized controlled trials are lacking. Neither targeted 
therapy with MEK inhibitors nor immune checkpoint block-
ade (ICB) demonstrated significantly improvement of the 
prognosis of patients with UM (Heppt et al. 2017b; Steeb 
et al. 2018). Thus, creating a solid and uniform framework 
or guideline for evidence-based treatment decisions remains 
challenging.
The management of UM is subject to country-specific 
regulations. Currently, only a few international and consen-
sus-based guidelines exist (Mathis et al. 2018; Nathan et al. 
2015; Simpson et al. 2014; Weis et al. 2016), a German 
guideline is currently not yet available. Besides, the care of 
patients with UM is organized in an interdisciplinary setting, 
involving ophthalmologists, oncologists, interventional radi-
ologists and dermato-oncologists. As current patterns of care 
are heterogeneous and the optimal management for patients 
with UM is yet to be determined, we performed a tri-national 
cross-sectional study to explore the current standard of care 
in German-speaking skin cancer centers.
Methods
As no validated survey existed for the objective of our study, 
the questionnaire with a total of 15 items was developed 
de-novo based on our institutional experience. The explora-
tive survey included questions in a multiple-choice format 
regarding various treatment approaches for primary and met-
astatic disease of ocular melanoma [i.e., UM and conjuncti-
val melanoma (CM)], follow-up of patients, as well as items 
related to interdisciplinary cooperation. The questionnaire 
was pre-tested by independent researchers for clarity and 
comprehension. Based on their suggestions, the question-
naire was revised to its final form. The full questionnaire is 
available upon request. We encouraged the centers to also 
reply to our survey in case that they had not seen any patients 
with UM in 2018.
The paper-based questionnaire was distributed via mail to 
70 skin cancer centers in Germany, Austria and Switzerland 
on 6 August 2019. A reminding letter was sent to all non-
responders prolonging the initially stated period for response 
from 2 up to 4 months to increase the response rate. Contact 
information of the 70 participating centers (69 certified skin 
cancer centers and one uncertified center) were obtained via 
OncoMap® by OnkoZert®, an independent institute by the 
German Cancer Society which is responsible for the inspec-
tion and certification of cancer centers and oncology centers 
in Germany, Austria, and Switzerland (https ://www.onkoz 
ert.de/). Participation was voluntary and each center was 
allowed to participate only once in the survey (cross-sec-
tional design). Answered questionnaires could be sent back 
via E-Mail, Fax, or regular mail.
Frequency distributions of responses for each item were 
calculated and reported descriptively as absolute values and 
percentages (%). Quantitative variables were expressed as 
median with ranges. Subgroup differences were explored 
with Mood’s Median-Test. A p-value of < 0.05 was consid-
ered as significant. Statistical analyses were conducted with 
SPSS (IBM SPSS Statistics version 25, IBM Corporation).
Results
Characteristics of the participating centers
Overall, 44 of 70 (62.9%) centers completed the question-
naire. Most of the responding centers were located in Ger-
many (88.6%, n = 39), three were located in Switzerland 
(6.8%) and two in Austria (4.5%). The majority (68.2%, 
30/44) represented university hospitals and one third munici-
pal or private hospitals (31.8%, 14/44) (Fig. 1a).
In 86.8% (33/38) of the centers, patients with UM or CM 
presented for the first time after histological confirmation 
of distant metastases, followed by presentation upon clini-
cal or radiological suspicion of distant metastases in 83.8% 
(31/38). In nearly half of the centers (52.6%, 20/38), UM or 
CM patients presented after treatment of the primary ocular 
tumor (Fig. 1b).
Patients with UM or CM were referred by ophthalmolo-
gists (87.2%, 34/39), hematologists/oncologists (71.8%, 
28/39), general practitioners (56.4%, 22/39), and radiologists 
(25.6%, 10/39) (Fig. 1c). Other professions mentioned in the 
free-text field included dermatologists (n = 3), patients them-
selves (n = 1), gastroenterologists (n = 1) or others (n = 3).
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Surveillance
A total of 460 patients with primary UM were estimated to 
be treated at the skin cancer centers in 2018. 396 of these 
460 patients with primary UM (86.1%) were treated in Ger-
man skin cancer centers. The number of patients undergo-
ing surveillance for UM at the skin cancer centers in 2018 
ranged from 0 to 100 (median 3). Overall, 11.4% (5/44) 
of the participating centers did not have any patients in 
surveillance. Notably, more patients were followed-up on 
in a university hospital setting than in municipal or private 
hospitals (p = 0.013).
Surveillance of uveal melanoma (stages I–IIIC)
Half of the centers (51.4%, 19/37) performed regular 
screening measures to detect metastatic disease after the 
primary diagnosis of UM in case of a high-risk profile, 
Fig. 1  a Geographical map of 
the responding certified skin 
cancer centers in Austria, Ger-
many, and Switzerland, b bar 
chart illustrating the timepoint 
of UM and CM patients’ first 
presentation to the skin cancer 
center, and c pattern of UM 
and CM patients’ referral by 
multidisciplinary professions to 
the skin cancer centers
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such as large primary tumor or high vertical tumor thick-
ness. Screening due to a high molecular risk profile such as 
monosomy 3 was performed in 32.4% (12/37). In contrast, 
35.1% (14/37) did not perform any screening measures. 
The surveillance was exclusively performed by ophthal-
mology departments in three centers.
When asked about the specific screening and diagnostic 
measures performed during follow-up care, 76.3% (29/38) 
reported liver sonography, followed by total-body exami-
nation (63.2%, 24/38), magnetic resonance imaging (MRI) 
(52.6%, 20/38), computed tomography (CT) scans (47.4%, 
18/38) and positron emission tomography–computed 
tomography (PET-CT) (21.1%, 8/38) (Fig.  2a). Other 
modalities were lymph node sonography (n = 3) and chest 
x-ray (n = 2).
Other screening measures stated in a free-text field com-
prised the assessment of serum biomarkers including S100 
(n = 4), melanoma inhibitory activity protein (MIA, n = 2), 
liver enzymes (n = 1), lactate dehydrogenase (LDH, n = 2) 
or tumor markers in general (n = 1). One center had no uni-
form guidelines but performed regular sonography or MRI 
of the liver. Another one adapted the recommendations for 
the follow-up of stage III cutaneous melanoma.
The majority performed follow-up examinations at inter-
vals of 3 months (66.7%, 22/33) or 6 months (51.5%, 17/33). 
Besides, three centers conducted surveillance at intervals 
of 12 months (9.1%), while one stated that intervals were 
longer than 12 months. No specific intervals were reported 
by three centers. Twenty-one centers provided more infor-
mation about the screening intervals in different years of 
follow-up (Fig. 2b). The screening intervals differed between 
centers especially when the time of follow-up was longer 
than 3 years. Twelve centers also provided detailed infor-
mation about distinct screening measurements and intervals 
(Table 1).
Management of metastatic disease
Overall, 249 patients with metastatic UM (median: 3, range 
0–50) were treated in 2018 in the participating centers. The 
median significantly differed between university and munici-
pal hospitals (p = 0.003), i.e., more patients with metastatic 
disease were followed-up on in university hospitals.
Most patients with metastatic disease (UM and CM) were 
treated in the skin cancer centers or dermatology depart-
ments (70.7%, 29/41), while 12.2% (5/41) indicated that 
Fig. 2  Bar chart illustrating a 
the deployed screening meas-
ures in the skin cancer centers 
for patients with UM b applied 
screening intervals in differ-
ent years of follow-up for UM. 
Abbreviations: CT: computed 
tomography, PET-CT: positron 
emission tomography–com-
puted tomography, MRI: mag-
netic resonance imaging, MIA: 
melanoma inhibitory antigen, 
LDH: lactate dehydrogenase
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patients were treated in hematology/oncology units only. 
In 5 centers (12.2%), patients with metastatic disease were 
treated both by skin cancer centers and hematology/oncol-
ogy units. One center reported simultaneous treatment in the 
ophthalmology and gastroenterology departments, respec-
tively. In one center, patients with metastatic disease were 
treated in the gastroenterology department.
We also investigated which systemic treatments were 
applied for metastatic UM in 2018. Nearly 80% of cent-
ers (35/40) applied nivolumab in combination with ipili-
mumab, followed by conventional chemotherapy (50%, 
20/40), nivolumab monotherapy (42.5%, 17/40), and pem-
brolizumab monotherapy (40%, 16/40) (Fig. 3a). Besides, 
MEK inhibitors and ipilimumab monotherapy were applied 
in 35% (14/40) and 15% (6/40), respectively. Other treat-
ments mentioned in a free-text field included tebentafusp 
(n = 5), sorafenib (n = 4) and cabozantinib (n = 1), BRAF 
plus MEK inhibitor (n = 1), dendritic cell vaccination (n = 1), 
and talimogene laherparepvec (n = 1).
As UM has a unique propensity for metastatic spread to 
the liver, we specifically investigated liver-directed treat-
ments (Collaborative Ocular Melanoma Study 2001). Selec-
tive internal radiation therapy (SIRT) was most frequently 
performed (79.4%; 27/34), followed by radiofrequency abla-
tion (RFA) with 58.8% (20/34), trans-arterial chemoembo-
lization (TACE) (55.9%, 19/34), and stereotactic radiation 
(50%, 17/34) (Fig. 3b).
Implications and unmet needs
At the end of the questionnaire, all responders were invited 
to raise general comments or wishes regarding the manage-
ment of UM. Most desired clear follow-up schemes for the 
surveillance of tumor-free patients with UM. Surveillance, 
especially regarding intervals and duration of follow-up, 
is currently not yet standardized, but rather individual. 
Guidelines are, therefore, desirable as currently treatment 
of patients with UM is mostly based on individual experi-
ence. Additionally, a central register for patients with ocular 
melanoma was suggested by one center.
Discussion
Uveal melanoma is a rare cancer condition of high unmet 
clinical need. The aim of our survey was to provide an 
overview of the current patterns of care and surveillance 
in German-speaking skin cancer centers. We focused on 
skin cancer centers as the treatment of metastatic disease is 
currently mostly performed in analogy to cutaneous mela-
noma including checkpoint blockade and kinase inhibitors. 
Not surprisingly, more patients were treated in follow-up 
care at university hospitals compared to municipal hospi-
tals. In 2016, 642 adult patients were newly diagnosed with 
ocular cancer (ICD-10 C69) in Germany, indicating that 
Table 1  Reported follow-up strategies for UM in the skin cancer centers in Austria, Germany, and Switzerland
Total-body 
examination

























3 months 5 2 1 - 5 2 - - 1 - - - 2 - - - - - - -
6 months 1 4 3 - 1 4 2 - 3 2 1 - 1 3 1 1 - - - -
12 months - - 2 - - - 1 - 2 2 1 - - - - - - - - -
Unclear 
(if necessary)
3 3 1 (1) 1 1
*MRI, CT, PET-CT, chest X-ray
**S100, LDH, MIA, liver enzymes
1768 Journal of Cancer Research and Clinical Oncology (2021) 147:1763–1771
1 3
the skin cancer centers represented in our survey treated 
approximately more than 70% of all newly diagnosed cases 
(Robert Koch-Institut 2020). Taking into account that up 
to 50% of all patients with UM develop distant metastases 
(Bedikian 2006) approximately 320 patients in Germany will 
be diagnosed with metastatic disease per year. In our sur-
vey, the skin cancer centers stated to care for 253 patients, 
indicating that in Germany, almost 80% of all patients with 
metastatic ocular melanoma, i.e., UM or CM, are treated in 
these departments. These numbers highlight the importance 
of skin cancer centers for the therapy and surveillance of 
patients with both primary and metastatic ocular melanoma.
Although UM differs from cutaneous melanoma both 
clinically and biologically, treatment options for advanced 
stages have largely been adopted from it, yet with much 
lower response rates and at the cost of high treatment-related 
toxicity (Heppt et al. 2017a, 2019). This makes it difficult to 
demonstrate the clinical effectiveness of interventions and 
to create a solid framework for evidence-based treatment 
decisions. Our survey among skin cancer centers in Ger-
many, Austria and Switzerland confirmed the urgent need for 
the development of clinical practice guidelines for this rare 
cancer entity, comparable to other consortia (Mathis et al. 
2018; Nathan et al. 2015; Simpson et al. 2014; Weis et al. 
2016). Special strategies need to be employed to generate 
evidence that is compatible with rigorous quality standards 
of guidelines (Pai et al. 2019). Previous assessments of the 
methodological quality of international guidelines on UM 
have identified weaknesses and strengths of existing guide-
lines which require particular attention and improvement 
in future guidelines (Steeb et al. 2020). A guideline from 
the United Kingdom published by Nathan et al. was rated 
as best and may hence serve as a basis for a future German 
guideline.
A further barrier towards the management of UM comes 
from the fact that the care of patients with UM occurs in 
a highly interdisciplinary setting, involving ophthalmolo-
gists, hematologists, oncologists, interventional radiologists 
and dermato-oncologists. This highlights the urgent need 
for an interdisciplinary guideline. For patients with primary 
disease, mostly ophthalmologists and radiation oncologists 
are involved in the care, while patients with metastatic dis-
ease are often referred to dermato-oncologists, which is in 
line with our sample. The majority of surveyed responders 
stated that patients presented to their center after the his-
tological confirmation of distant metastases. Thus, ICB is 
often adopted as therapeutic strategy from cutaneous mela-
noma with 80% of centers treating metastatic patients with 
Fig. 3  Bar charts illustrating a 
available systemic treatments 
in the skin cancer centers and 
b liver-directed approaches for 
the management of metastatic 
UM and CM. Abbreviations: 
DC: dendritic cell, T-VEC: tali-
mogene laherparepvec, SIRT: 
selective internal radiation 
therapy, RFA: radiofrequency 
ablation, TACE: trans-arterial 
chemoembolization
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nivolumab plus ipilimumab. Beside the broad usage of ICB, 
chemotherapy was also often applied although it has only 
limited efficacy irrespective of the chemotherapeutic agent 
(Carvajal et al. 2017). This underlines that novel treatment 
strategies are utterly needed. Clinical studies investigating 
new treatment options as, e.g., tebentafusp (IMCgp100), 
a bispecific protein bridging CD3 +  T cells and gp100-
expressing tumor cells (Liddy et al. 2012) have shown prom-
ising results in phase I/II trials so far (Carvajal et al. 2018; 
Middleton et al. 2016).
Screening and follow-up of patients varied the most 
across our sample. Some followed the evidence- and con-
sensus-based guideline for stage III cutaneous melanoma 
(Eigentler et al. 2017), while others based their follow-up 
schedule on the recommendations established within their 
institution or on personal experience. This highlights again 
the urgent need for uniform recommendations which should 
be based on progression and recurrence rate.
There are several limitations of this study. The response 
rate was limited to 44 of 70 skin cancer centers. Besides this, 
university hospitals were overrepresented, thus diminish-
ing the overall representability of the results. Furthermore, 
recall bias may be likely as the participating centers had 
to remember management of patients of the years before. 
Additionally, in some items, the answers of the participants 
differed extremely for instance when reporting the follow-up 
schemes, ranging from only brief descriptions to detailed 
reports including follow-up intervals and screening meth-
ods. However, to the best of our knowledge, practice and 
surveillance patterns in German-speaking countries have not 
been investigated so far, and therefore, our results represent 
a first step towards standardized care for patients with ocular 
melanoma.
Our results will contribute to improve nationwide man-
agement of ocular melanoma and to deduce possible future 
projects within the German Dermatologic Cooperative 
Oncology Group (DeCOG).
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